Zeteo Biomedical LLC Newsroom - Profile and News Archive

CEDAR PARK, Texas, Feb. 19, 2025 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical LLC today announced the launch of its ZTech-P CygnusMR™ and CygnusSDX™ delivery devices, designed for precise, metered-unit dosing of dry powder drugs and biologics via systemic nasal and nose-to-brain administration. These innovative needle-free delivery systems provide pharmaceutical and biotech companies with advanced solutions to accelerate the development, clinical evaluation, and commercial deployment of dry powder nasal combination products for a broad range of therapeutic applications.

PFLUGERVILLE, Texas, May 4, 2022 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical LLC announced today the availability of the ZEOx1 OrionMRQ™ nasal drug and vaccine delivery device. Zeteo’s latest innovative delivery device provides pharmaceutical and biotech companies developing drugs, peptides, proteins, monoclonal antibodies and vaccines with precise, metered unit dose systemic delivery via the nasal route.

AUSTIN, Texas, March 10, 2021 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical, a privately held, biomedical device company, announced today it has been awarded a United States Patent for its “Oral Delivery Device and Methods” (US Patent 10238577). This latest patent expands the capabilities of Zeteo’s ZEO Delivery Platform to systemically deliver drugs or biologics, into the body non-invasively via the sublingual route.

AUSTIN, Texas, Nov. 17, 2020 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.